Warfarin-induced skin necrosis in HIV-infected patients with tuberculosis and venous thrombosis

Simple item page
dc.contributor.authorBhaijee, F
dc.contributor.authorWainwright, H
dc.contributor.authorMeintjes, G
dc.contributor.authorWilkinson, R J
dc.contributor.authorTodd, G
dc.contributor.authorde Vries, E
dc.contributor.authorPepper, D J
dc.date.accessioned2017-07-06T09:40:41Z
dc.date.available2017-07-06T09:40:41Z
dc.date.issued2010
dc.date.updated2016-01-12T08:57:54Z
dc.description.abstractBackground. At the turn of the century, only 300 cases of warfarin-induced skin necrosis (WISN) had been reported. WISN is a rare but potentially fatal complication of warfarin therapy. There are no published reports of WISN occurring in patients with HIV-1 infection or tuberculosis (TB). Methods. We retrospectively reviewed cases of WISN presenting from April 2005 to July 2008 at a referral hospital in Cape Town, South Africa. Results. Six cases of WISN occurred in 973 patients receiving warfarin therapy for venous thrombosis (0.62%, 95% CI 0.25 - 1.37%). All 6 cases occurred in HIV-1-infected women (median age 30 years, range 27 - 42) with microbiologically confirmed TB and venous thrombosis. All were profoundly immunosuppressed (median CD4+ count at TB diagnosis 49 cells/µl, interquartile range 23 - 170). Of the 3 patients receiving combination antiretroviral therapy, 2 had TB-IRIS (immune reconstitution inflammatory syndrome). The median interval from initiation of antituberculosis treatment to venous thrombosis was 37 days (range 0 - 150). The median duration of parallel heparin and warfarin therapy was 2 days (range 1 - 6). WISN manifested 6 days (range 4 - 8) after initiation of warfarin therapy. The international normalised ratio (INR) at WISN onset was supra-therapeutic, median 5.6 (range 3.8 - 6.6). Sites of WISN included breasts, buttocks and thighs. Four of 6 WISN sites were secondarily infected with drug-resistant nosocomial bacteria (methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter, extendedspectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae) 17 - 37 days after WISN onset. In 4 patients, the median interval from WISN onset to death was 43 days (range 25 - 45). One of the 2 patients who survived underwent bilateral mastectomies and extensive skin grafting at a specialist centre. Conclusion. This is one of the largest case series of WISN. We report a novel clinical entity: WISN in HIV-1 infected patients with TB and venous thrombosis. The occurrence of 6 WISN cases in a 40-month period may be attributed to (i) hypercoagulability, secondary to HIV-1 and TB; (ii) short concurrent heparin and warfarin therapy; and (iii) high loading doses of warfarin. Active prevention and appropriate management of WISN are likely to improve the dire morbidity and mortality of this unusual condition.
dc.identifier.apacitationBhaijee, F., Wainwright, H., Meintjes, G., Wilkinson, R. J., Todd, G., de Vries, E., & Pepper, D. J. (2010). Warfarin-induced skin necrosis in HIV-infected patients with tuberculosis and venous thrombosis. <i>South African Medical Journal</i>, http://hdl.handle.net/11427/24705en_ZA
dc.identifier.chicagocitationBhaijee, F, H Wainwright, G Meintjes, R J Wilkinson, G Todd, E de Vries, and D J Pepper "Warfarin-induced skin necrosis in HIV-infected patients with tuberculosis and venous thrombosis." <i>South African Medical Journal</i> (2010) http://hdl.handle.net/11427/24705en_ZA
dc.identifier.citationWainwright, H;Meintjes, Graeme;Pepper, Dominique;, hai. (2010). Warfarin-induced skin necrosis in HIV-infected patients with tuberculosis and venous thrombosis, 100
dc.identifier.ris TY - Journal Article AU - Bhaijee, F AU - Wainwright, H AU - Meintjes, G AU - Wilkinson, R J AU - Todd, G AU - de Vries, E AU - Pepper, D J AB - Background. At the turn of the century, only 300 cases of warfarin-induced skin necrosis (WISN) had been reported. WISN is a rare but potentially fatal complication of warfarin therapy. There are no published reports of WISN occurring in patients with HIV-1 infection or tuberculosis (TB). Methods. We retrospectively reviewed cases of WISN presenting from April 2005 to July 2008 at a referral hospital in Cape Town, South Africa. Results. Six cases of WISN occurred in 973 patients receiving warfarin therapy for venous thrombosis (0.62%, 95% CI 0.25 - 1.37%). All 6 cases occurred in HIV-1-infected women (median age 30 years, range 27 - 42) with microbiologically confirmed TB and venous thrombosis. All were profoundly immunosuppressed (median CD4+ count at TB diagnosis 49 cells/µl, interquartile range 23 - 170). Of the 3 patients receiving combination antiretroviral therapy, 2 had TB-IRIS (immune reconstitution inflammatory syndrome). The median interval from initiation of antituberculosis treatment to venous thrombosis was 37 days (range 0 - 150). The median duration of parallel heparin and warfarin therapy was 2 days (range 1 - 6). WISN manifested 6 days (range 4 - 8) after initiation of warfarin therapy. The international normalised ratio (INR) at WISN onset was supra-therapeutic, median 5.6 (range 3.8 - 6.6). Sites of WISN included breasts, buttocks and thighs. Four of 6 WISN sites were secondarily infected with drug-resistant nosocomial bacteria (methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter, extendedspectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae) 17 - 37 days after WISN onset. In 4 patients, the median interval from WISN onset to death was 43 days (range 25 - 45). One of the 2 patients who survived underwent bilateral mastectomies and extensive skin grafting at a specialist centre. Conclusion. This is one of the largest case series of WISN. We report a novel clinical entity: WISN in HIV-1 infected patients with TB and venous thrombosis. The occurrence of 6 WISN cases in a 40-month period may be attributed to (i) hypercoagulability, secondary to HIV-1 and TB; (ii) short concurrent heparin and warfarin therapy; and (iii) high loading doses of warfarin. Active prevention and appropriate management of WISN are likely to improve the dire morbidity and mortality of this unusual condition. DA - 2010 DB - OpenUCT DP - University of Cape Town J1 - South African Medical Journal LK - https://open.uct.ac.za PB - University of Cape Town PY - 2010 T1 - Warfarin-induced skin necrosis in HIV-infected patients with tuberculosis and venous thrombosis TI - Warfarin-induced skin necrosis in HIV-infected patients with tuberculosis and venous thrombosis UR - http://hdl.handle.net/11427/24705 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/24705
dc.identifier.vancouvercitationBhaijee F, Wainwright H, Meintjes G, Wilkinson RJ, Todd G, de Vries E, et al. Warfarin-induced skin necrosis in HIV-infected patients with tuberculosis and venous thrombosis. South African Medical Journal. 2010; http://hdl.handle.net/11427/24705.en_ZA
dc.language.isoeng
dc.publisher.departmentInstitute of Infectious Disease and Molecular Medicineen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.sourceSouth African Medical Journal
dc.source.urihttp://www.samj.org.za/index.php/samj/index
dc.titleWarfarin-induced skin necrosis in HIV-infected patients with tuberculosis and venous thrombosis
dc.typeJournal Articleen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Wainwright_Article_2010.pdf
Size:
1.87 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.72 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles